- Seres misses on earnings and revenue, although revenue was up 344% to $144.92 million.
- Net loss of $50.00 million in Q4 compared with $18.3 million in Q4 2020, due significantly to preparing for launch of SER-109.
- Key publication on SER-109 C.difficile results and signs remain good for FDA approval.
- Progress in the Ulcerative Colitis program is encouraging, as was the quality of Q4 questions and sophistication of management answers.
- Microbiomics is becoming increasingly well defined as a new treatment area even though the first real products are still being defined. I think Seres remains positioned to become successful.
For further details see:
Seres Therapeutics Is Playing A Long Game